论文部分内容阅读
幽门螺杆菌(HP)是慢性胃炎的主要病因,在消化性溃疡发病中起重要作用。国内外学者近十几年的研究结果表明,HP和胃癌之间具有相关性,而胃粘膜肠上皮化生(IM)及非典型增生(GED)被认为是一种常见的胃粘膜癌前病变,最终可导致癌变的结果。用中西药抗HP治疗是否可以促使肠上皮化生及非典型增生的逆转,阻止其发生癌变,是降低胃癌发病率的一个重要环节。我院从HP感染及中西药抗HP治疗的角度,探讨其与肠上皮化生及非典型增生的相关性,力求为临床预防胃癌的发生寻找一条新的途径。
Helicobacter pylori (HP) is the main cause of chronic gastritis and plays an important role in the pathogenesis of peptic ulcer. Nearly ten years of domestic and foreign scholars’ research results show that there is a correlation between HP and gastric cancer, and gastric mucosa intestinal metaplasia (IM) and atypical hyperplasia (GED) is considered as a common gastric precancerous lesions , Can eventually lead to the result of cancer. With Chinese and Western medicine anti-HP treatment can promote intestinal metaplasia and atypical hyperplasia reversal, prevent its occurrence of cancer, is to reduce the incidence of gastric cancer is an important part. Our hospital from the perspective of HP infection and anti-HP treatment of Chinese and Western medicine to explore its correlation with intestinal metaplasia and atypical hyperplasia, and strive to find a new way for the clinical prevention of gastric cancer.